Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Arcturus Therapeutics Holdings has reported Capital Expenditures for 8 years, with the latest figure at $143000.0 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $143000.0; the trailing twelve-month figure through Mar 2026 stood at $93000.0 (down 82.94% YoY), and the FY2025 full-year result was $230000.0, down 64.51% from the prior year.
• Capital Expenditures for Q4 2025 stood at $143000.0, up from -$50000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $3.8 million in Q4 2022, with the low at -$2.2 million in Q4 2021.
• Historically, Capital Expenditures has averaged $642111.1 across 5 years, with a median of $262000.0 in 2021.
• The largest YoY upside for Capital Expenditures was 786.97% in 2022 against a maximum downside of 233.1% in 2022.
• Arcturus Therapeutics Holdings' Capital Expenditures stood at -$2.2 million in 2021, then soared by 270.34% to $3.8 million in 2022, then sank by 77.02% to $875000.0 in 2023, then plunged by 90.86% to $80000.0 in 2024, then soared by 78.75% to $143000.0 in 2025.
• The last three Capital Expenditures figures came in at $143000.0 (Q4 2025), -$50000.0 (Q3 2025), and $137000.0 (Q1 2025), per Business Quant data.